Antibiotic policies to control hospital-acquired infection

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 4, 2008, Pages 763-765

  Gould, I M ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

Clostridium difficile; MRSA; Randomized controlled trials; Stewardship

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BACTERIAL TOXIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM; CARBAPENEMASE; CEPHALOSPORIN DERIVATIVE; FIBRONECTIN BINDING PROTEIN; MACROLIDE; METICILLIN; POLYMYXIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOXIC SHOCK SYNDROME TOXIN 1; VANCOMYCIN; VIRULENCE FACTOR;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL FLORA; BACTERIAL GROWTH; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; BIOFILM; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE; COCHRANE LIBRARY; COMMUNITY ACQUIRED PNEUMONIA; DRUG CHOICE; DRUG EXPOSURE; EDITORIAL; ENTEROBACTERIACEAE; ENZYME SYNTHESIS; EVIDENCE BASED MEDICINE; GRAM NEGATIVE BACTERIUM; HEALTH CARE POLICY; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; MEDICAL DECISION MAKING; MEDICAL RESEARCH; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; HOSPITALS; HUMANS; INFECTION CONTROL; ORGANIZATIONAL POLICY;

EID: 41149165823     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn039     Document Type: Editorial

References (34)

1. Gould IM. The clinical significance of methicillin-resistant Staphylococcus aureus. J Hosp Infect 2005; 61: 277-82.
2. Davey P, Brown E, Fenelon L et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2005; issue 4: CD003543.
3. Gould IM. A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother 1999; 43: 459-65.
4. Monnet DL, MacKenzie FM, Skov R et al. Fighting MRSA in hospitals: time to restrict the broad use of specific antimicrobial classes? J Hosp Infect 2005; 6: 267-8.
5. Bosso JA, Mauldin PD. Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of Gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 2106-12.
6. Charbonneau P, Parienti J, Thibon P et al. Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: A quasi experimental study. Clin Infect Dis 2006; 42: 778-84.
7. Berntsen CA, McDermott W. Increased transmissibility of staphylococci to patients receiving an antimicrobial drug. New Engl J Med 1960; 262: 637-42.
8. Goerke C, Koller J, Wolz C. Ciprofloxacin and trimethoprim cause phage induction and virulence modulation in Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 171-7.
9. Maiques E, Ubeda C, Campoy S et al. β-Lactam antibiotics induce the SOS response and horizontal transfer of virulence factors in Staphylococcus aureus. J Bacteriol 2006; 188: 2726-9.
10. Taylor CM, Riordan FAI; Graham C. New football boots and toxic shock syndrome. BMJ 2006; 332: 1376-8.
11. Bisognano C, Vaudaux P, Rohner P et al. Induction of fibronectin-binding proteins and increased adhesion of quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin. Antimicrob Agents Chemother 2000; 44: 1428-37.
12. Sakoulas G, Moellering RC Jr, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis 2006; 42 Suppl 1: S40-50.
13. Sendi P, Rohrbach M, Graber P et al. Staphylococcus aureus small colony variants in prosthetic joint infection. Clin Infect Dis 2006; 43: 961-7.
14. Grundmann H, Barwolff S,, Tami A et al. How many infections are caused by patient-to-patient transmission in intensive care units? Crit Care Med 2005; 33: 946-51.
15. Silvestri L, van Saene HKF, Milanese M et al. Selective decontamination of the digestive tract reduces bacterial bloodstream infection and mortality in critically ill patients. Systemic review of randomized, controlled trials. J Hosp Infect 2007; 65: 187-203.
16. Aboelela SW, Saiman L, Stone P et al. Effectiveness of barrier precautions and surveillance cultures to control transmission of multidrug-resistant organisms: A systematic review of the literature. Am J Infect Control 2006; 34: 484-94.
17. Aboelela SW, Stone PW, Larson EL. Effectiveness of bundled behavioural interventions to control healthcare-associated infections: A systematic review of the literature. J Hosp Infect 2007; 66: 101-8.
18. McCaig LF, Besser RE, Hughes JM. Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000. Emerg Infect Dis 2003; 9: 432-7.
19. Livermore DM, Reynolds R, Stephens P et al. Trends in penicillin and macrolide resistance among pneumococci in the UK and the Republic of Ireland in relation to antibiotic sales to pharmacies and dispensing doctors. Int J Antimicrob Agents 2006; 28: 273-9.
20. Roberts J, Chandra M, Pebody R et al. Variation in incidence of pneumococcal and meningococcal disease across Europe. Euro Surveil 2007; 12: E071115.5. http://www.eurosurveillance.org/ew/2007/ 071115.asp#.
21. Szumowski JD, Cohen DE, Kanaya F et al. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 2007; 51: 423-8.
22. Livermore DM, Hawkey PM. CTX-M: Changing the face of ESBLs in the, UK. J. Antimicrob Chemother 2005; 56: 451-4.
23. Bal AM, Gould IM. Empirical antimicrobial treatment for chemotherapy-induced febrile neutropenia. Int J Antimicrob Agents 2007; 29: 501-9.
24. Ling TKW, Xiong J, Yu Y et al. Multicenter antimicrobial susceptibility survey of Gram-negative bacteria isolated from patients with community-acquired infections in the People's Republic of China. Antimicrob Agents Chemother 2006; 50: 374-8.
25. Falagas ME, Kasiakou SK. Correct use of the term pan-drug-resistant' (PDR) Gram-negative bacteria. Clin Microbiol Infect 2005; 11 1049-50.
26. Sánchez A, Salso, S, Culebras E et al. [Carbapenem resistance determined by metalloenzymes in clinical isolates of Pseudomonas aeruginosa]. Rev Esp Quimioter 2004; 17: 336-40.
27. Bal AM, Gould IM. Antibiotic resistance Staphylococcus aureus and its relevance in therapy. Expert Opin Pharmacother 2005; 6: 2257-69.
28. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2: S27-72.
29. British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001; 56 Suppl 4: Iv1-64.
30. Anon. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
31. Monnet DL, MacKenzie FM, Lopez-Lozano JM et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000. Emerg Infect Dis 2004; 10: 1432-41.
32. Kim JH, Gallis HA. Observations on spiraling empiricism: Its causes, allure, and perils, with particular reference to antibiotic therapy. Am J Med 1989; 87: 201-6.
33. Neuhaus T, Ewig S. Defining severe community-acquired pneumonia. Med Clin North Am 2001; 85: 1413-25.
34. Gould IM. Antibiotic use - ecological issues and required actions. In Antibiotic Policies: Theory and Practice, Chapter 35. New York: Kluwer Academic/Plenum Publishers, 2005.